EGFR and non-small cell lung carcinoma: Therefore, EGFR-targeted therapy has become a new strategy for NSCLC therapy.[14] Currently, cetuximab and necitumumab are the two most commonly used anti-EGFR monoclonal antibodies (mAbs).